Printer Friendly Version
Printer Friendly Version
Printer Friendly Version
A.7.01.05
A cochlear implant is a device for treatment of severe-to-profound hearing loss in individuals who only receive limited benefit from amplification with hearing aids. A cochlear implant provides direct electrical stimulation to the auditory nerve, bypassing the usual transducer cells that are absent or nonfunctional in deaf cochlea.
The basic structure of a cochlear implant includes both external and internal components. The external components include a microphone, an external sound processor, and an external transmitter. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear.
Sounds picked up by the microphone are carried to the external sound processor, which transforms sound into coded signals that are then transmitted transcutaneously to the implanted internal receiver. The receiver converts the incoming signals into electrical impulses that are then conveyed to the electrode array, ultimately resulting in stimulation of the auditory nerve.
Several cochlear implants are commercially available in the United States and are manufactured by Cochlear Americas, Advanced Bionics,and the MED-ELCorp. Over time, subsequent generations of the various components of the devices have been approved by the U.S. Food and Drug Administration (FDA), focusing on improved electrode design and speech-processing capabilities. Furthermore, smaller devices and the accumulating experience in children have resulted in broadening of the selection criteria to include children as young as 12 months. The FDA-labeled indications for currently marketed implant devicesare summarized below.
FDA-Approved Cochlear Implant Systems
Variables | Manufacturer and Currently Marketed Cochlear Implants | |||
Device | Advanced Bionics® HiResolution® Bionic Ear System (HiRes 90K) | Cochlear®Nucleus 22 and 24 | Med El® Maestro Combi 40+ | Neuro Cochlear Implant System (Oticon Medical) |
PMA | P960058 | P840024, P970051 | P000025 | P200021 |
Indications | ||||
Adults ≥18 y | Severe to profound unilateral SNHL (SSD or AHL) PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz of >80 dB HL Normal or near normal hearing in the contralateral ear defined as PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz of ≤ 30 dB HL | Moderate-to-profound bilateral SNHL defined asPTA at 250 Hz, 500 Hz, and 1000 Hz of >40 dB HL and ≤65 HL at 3000-8000 Hz SSD (≥90 dB) or AHL (Δ15 dB PTA) Limited benefit from unilateral amplification, defined by test scores of 50% or less on monosyllabic CNC words in quiet when tested in the ear to be implanted alone and 60% or less in the non-implant ear Patients must have at least 1 month experience wearing a CROS hearing aid or other relevant device and not show any subjective benefit, but radiological evidence of cochlear ossification may preclude a hearing aid trial | Severe-to-profound bilateral SNHL (≥70 dB at 500, 1000, and 2000 Hz) Limited benefit from appropriately fit hearing aids, defined as scoring ≤50% correct HINT sentences in quiet or noise with best-sided listening condition | |
Children | 12 mo to 17 y of age Profound bilateral SNHL(>90 dB) Use of appropriately fitted hearing aids for at least 6 mo in children 2 to 17 y or at least 3 mo in children 12 to 23 mo Lack of benefit in children <4 y is defined as a failure to reach developmentally appropriate auditory milestones (eg, spontaneous response to name in quiet or to environmental sounds) measured using IT-MAIS or MAIS or <20% correct on a simple open-set word recognition test (MLNT) administered using monitored live voice (70 dB SPL) Lack of hearing aid benefit in children >4 y defined asscoring <12% on a difficult open-set word recognition test (PBK test) or <30% on an open-set sentence test (HINT for Children) administered using recorded materials in the sound field (70 dB SPL) | 25 mo to 17 y, 11 mo of age Severe-to-profound bilateralSNHL MLNT scores ≤30% in best-aided condition in children LNT scores ≤30% in best-aided condition in children 9 to 24 mo of age Profound SNHLbilaterally Limited benefit from appropriate binaural hearing aids 5 y to 18 y of age Severe to profound unilateral SNHL (SSD or AHL) PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz of > 80 dB HL Normal or near normal hearing in the contralateral ear defined as PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz of ≤ 30 dB HL Limited benefit from an appropriately fitted unilateral hearing device | 12 mo to 18 y of age 5 y to 18 y of age SSD (≥90 dB) or AHL (Δ15 dB PTA) Insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 5% or less on developmentally appropriate monosyllabic word lists when tested in the ear to be implanted Patients must have at least 1 month experience wearing a CROS hearing aid or other relevant device and not show any subjective benefit | Not Applicable |
AHL: asymmetric hearing loss; CNC: consonant-nucleus-consonant; CROS: contralateral routing of signal; HINT: Hearing in Noise Test; HL: hearing loss; IT-MAIS: Infant-Toddler Meaningful Auditory Integration Scale; LNT: Lexical Neighborhood Test; MAIS: Meaningful Auditory Integration Scale; MLNT: Multisyllabic Lexical Neighborhood Test; PBK: Phonetically Balanced-Kindergarten; PMA: premarket approval; PTA: pure tone average; SNHL: sensorineural hearing loss; SPL: sound pressure level; SSD: single-sided deafness.
In 2014, the Nucleus® Hybrid™ L24 Cochlear Implant System (Cochlear Americas) was approved by the FDA through the premarket approval process. This system is a hybrid cochlear implant and hearing aid, with the hearing aid integrated into the external sound processor of the cochlear implant. It is indicated for unilateral use in patients aged 18 years and older who have residual low-frequency hearing sensitivity and severe-to-profound high-frequency sensorineural hearing loss, and who obtain limited benefit from an appropriately fit bilateral hearing aid. The electrode array inserted into the cochlea is shorter than conventional cochlear implants. According to the FDA’s premarket approval notification, labeled indications for the device include:
Preoperative hearing in the range from "normal to moderate hearing loss (HL) in the low frequencies (thresholds no poorer than 60 dB hearing loss (HL) up to and including 500 Hz)."
Preoperative hearing with "severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥75 dB HL) in the ear to be implanted."
Preoperative hearing with "moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥60 dB HL) in the contralateral ear."
"The Consonant-Nucleus-Consonant (CNC) word recognition score will be between 10% and 60%, inclusively, in the ear to be implanted in the preoperative aided condition and in the contralateral ear equal to or better than that of the ear to be implanted but not more than 80% correct."
In 2022, the Nucleus® Hybrid™ L24 Cochlear Implant System received expanded approval for single-sided deafness or unilateral hearing loss in adults and children age 5 or older (P970051/S205).
Other hybrid hearing devices have been developed. The Med-El EAS System received expanded premarket approval by the FDA in 2016 (PMA P000025/S084).
Although cochlear implants have typically been used unilaterally, interest in bilateral cochlear implantation has arisen in recent years. The proposed benefits of bilateral cochlear implants are to improve understanding of speech occurring in noisy environments and localization of sounds. Improvements in speech intelligibility with bilateral cochlear implants may occur through binaural summation (i.e., signal processing of sound input from two sides may provide a better representation of sound and allow the individual to separate noise from speech). Speech intelligibility and localization of sound or spatial hearing may also be improved with head shadow and squelch effects (i.e., the ear that is closest to the noise will receive it at a different frequency and with different intensity, allowing the individual to sort out the noise and identify the direction of sound). Bilateral cochlear implantation may be performed independently with separate implants and speech processors in each ear, or a single processor may be used. However, no single processor for bilateral cochlear implantation has been FDA approved for use in the United States. Also, single processors do not provide binaural benefit and may impair sound localization and increase the signal-to-noise ratio received by the cochlear implant.
Bilateral or unilateral cochlear implantation of a U.S. Food and Drug Administration (FDA)-approved cochlear implant may be considered medically necessary in individuals ages 9 months and older with bilateral severe-to-profound pre-or post-lingual (sensorineural) hearing loss, defined as a hearing threshold pure-tone average of 70 dB (decibels) hearing loss or greater at 500 Hz (hertz), 1000 Hz, and 2000 Hz, who have shown limited or no benefit from hearing aids.
Cochlear implantation as a treatment for individuals with unilateral hearing loss with or without tinnitus is considered investigational.
Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model, are considered investigational.
Replacement of internal and/or external components solely for the purpose of upgrading to a system with advanced technology or to a next-generation device is considered investigational.
Replacement of internal and/or external components is considered medically necessary only in a small subset of members who have inadequate response to existing component(s) to the point of interfering with the individual’s activities of daily living, or the component(s) is/are no longer functional and cannot be repaired.
Cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (eg, the Nucleus® Hybrid™ L24 Cochlear Implant System) may be considered medically necessary for individuals ages 18 years and older who meet all of the following criteria:
Bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity; AND
Receive limited benefit from appropriately fit bilateral hearing aids; AND
Have the following hearing thresholds:
Low-frequency hearing thresholds no poorer than 60 dB hearing level up to and including 500 Hz (averaged over 125, 250, and 500 Hz) in the ear selected for implantation; AND
Severe-to-profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥75 dB hearing level) in the ear to be implanted; AND
Moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz ≥60 dB hearing level) in the contralateral ear; AND
Aided consonant-nucleus-consonant word recognition score from 10% to 60% in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80% correct.
Note: Auditory Brainstem Implant , designed to restore hearing in patients with neurofibromatosis who are deaf secondary to removal of bilateral acoustic neuromas, is not addressed in this policy.
Federal Employee Program (FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Bilateral cochlear implantation should be considered only when it has been determined that the alternative of unilateral cochlear implantation plus hearing aid in the contralateral ear will not result in a binaural benefit (i.e., in those individuals with hearing loss of a magnitude where a hearing aid will not produce the required amplification).
In certain situations, implantation may be considered before 12 months of age. One scenario is after meningitis when cochlear ossification may preclude implantation. Another is in cases with a strong family history, because establishing a precise diagnosis is less uncertain.
Hearing loss is rated on a scale based on the threshold of hearing. Severe hearing loss is defined as a bilateral hearing threshold of 70 to 90 dB, and profound hearing loss is defined as a bilateral hearing threshold of 90 dB and above.
In adults, limited benefit from hearing aids is defined as scores of 50% correct or less in the ear to be implanted on tape-recorded sets of open-set sentence recognition. In children, limited benefit is defined as failure to develop basic auditory skills, and in older children, <30% correct on open-set tests.
A post cochlear implant rehabilitation program is necessary to achieve benefit from the cochlear implant. The rehabilitation program consists of 6 to 10 sessions that last approximately 2½ hours each. The rehabilitation program includes development of skills in understanding running speech, recognition of consonants and vowels, and tests of speech perception ability.
Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation.Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.
Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Mental Health Disorders, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:
A. consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and
B. appropriate with regard to standards of good medical practice; and
C. not solely for the convenience of the Member, his or her Provider; and
D. the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.
For the definition of medical necessity, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary.
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
7/1992: Approved by Medical Policy Advisory Committee (MPAC)
12/30/1999: Policy Guidelines updated
9/21/2001:Policy rewritten to be reflective of Blue Cross Blue Shield Association policy # 7.01.05, Code Reference section updated, CPT code 92507, 92510 added
11/2001: Reviewed by MPAC; revisions approved
4/18/2002: Type of Service and Place of Service deleted
5/29/2002: Code Reference section updated, CPT code 69949 added, HCPCS L8619, V5269, V5273, V5299, V5336, V5362, V5363 added
3/6/2003: Code Reference section updated, CPT code 92601, 92602, 92603, 92604 added
7/15/2004: Reviewed by MPAC, bilateral cochlear implantation considered investigational, Description section aligned with BCBSA policy # 7.01.05, definition of investigational added Policy Guidelines, Sources updated
10/5/2004: Code Reference section updated, CPT code 69949 deleted, CPT 92507 description revised, CPT 92508 added, ICD-9 procedure code 20.96, 20.97, 20.99, 95.49 added, ICD-9 diagnosis code range 389.10-389.18 listed separately, ICD-9 diagnosis 389.7 added, HCPCS L8619 note added, HCPCS V5269, V5273, V5299, V5336, V5362, V5363 deleted
3/22/2005: Code Reference section updated, CPT code 92510 description revised, HCPCS L8615, L8616, L8617, L8618 with Note: "See POLICY GUIDELINES for information regarding replacement of the external component of the cochlear implant" and effective date of 1/1/2005 added.
11/15/2005: HCPCS codes K0731, K0732, L8620 added
03/10/2006: Coding updated. CPT4 / HCPCS 2006 revisions added to policy
03/13/2006: Policy reviewed, no changes
09/13/2006: Coding updated. ICD9 2006 revisions added to policy
12/27/2006: Code Reference section updated per the 2007 HCPCS revisions
3/27/2007: Policy reviewed, no changes to policy statement. Bilateral cochlear implantation added to Policy Guidelines section
06/26/2007: Policy statement updated; bilateral cochlear implantation changed from investigational to may be considered medically necessary
7/19/2007: Reviewed and approved by MPAC
9/18/2007: Code reference section updated. ICD-9 2007 revisions added to policy
1/7/2009: Policy reviewed, policy section partially rewritten and clarified.
3/12/2010: Code Reference section updated. New HCPCS codes L8627, L8628 and L8629 added to covered table.
04/26/2010: Policy description updated regarding devices. Policy statements modified for clarity; intent unchanged. Contraindications to cochlear implantation added to the policy guidelines. FEP verbiage added to the Policy Exceptions section. Deleted outdated references from the Sources section. Removed deleted CPT code 92510 from the codes table as this code was deleted on 12/31/2005.
08/02/2011: Policy reviewed; no changes.
07/17/2012: Policy reviewed; no changes.
05/08/2013: Removed deleted CPT code 92510 from the Code Reference section.
11/15/2013: Policy statement updated to add the following: Cochlear implantation as a treatment for patients with unilateral hearing loss with or without tinnitus is considered investigational. Deleted the following unilateral hearing loss ICD-9 diagnosis codes from the Code Reference section: 389.13, 389.15, and 389.17.
09/15/2014: Policy statement updated to state that cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant, including but not limited to the Nucleus® Hybrid™ L24 Cochlear Implant System, is considered investigational. Policy guidelines and policy description updated regarding hybrid devices.
08/25/2015: Code Reference section updated for ICD-10.
09/25/2015: Policy description updated regarding devices. Medically necessary policy statement updated to make correction: "100 HZ" updated to "1000 HZ." Policy Guidelines section updated regarding cochlear ossification and to add medically necessary and investigative definitions.
05/31/2016: Policy number A.7.01.05 added.
09/30/2016: Code Reference section updated to add new ICD-10 diagnosis codes H90.A21 and H90.A22.
11/30/2016: Policy description updated regarding devices. Policy statement regarding cochlear implantation with a hybrid cochlear implant/hearing aid device changed from investigational to medically necessary with certain criteria. Policy Guidelines updated to remove information regarding hybrid cochlear implant devices.
03/02/2017: Policy description updated. Policy section updated to add that replacement of internal and/or external components solely for the purpose of upgrading to a system with advanced technology or to a next-generation device is considered not medically necessary. Added statement that replacement of internal and/or external components is considered medically necessary in members who have inadequate response to existing component(s) to the point of interfering with the individual's activities of daily living, or the component(s) is/are no longer functional and cannot be repaired.
12/22/2017: Code Reference section updated to add new 2018 HCPCS code L8625. Revised descriptions for HCPCS codes L8618 and L8624.
02/28/2018: Policy description updated regarding cochlear implant systems. Policy statements unchanged.
03/20/2019: Policy description updated with minor wording change. Policy statements unchanged.
03/10/2020: Policy description updated regarding devices. Policy statements unchanged.
09/01/2021: Policy description updated regarding device indications. Medically necessary policy statement regarding bilateral or unilateral cochlear implantation updated to change age requirement from "12 months and older" to "9 months and older." Policy Guidelines updated to change "Nervous/Mental Conditions" to "Mental Health Disorders" and "Medically Necessary" to "medical necessity."
04/11/2022: Policy description updated regarding devices and indications. Policy statements unchanged.
03/24/2023: Policy description updated regarding devices. Policy statements updated to change "patients" to "individuals" and "not medically necessary" to "investigational." Policy Guidelines updated.
03/20/2024: Policy description updated with minor changes. Policy statements unchanged.
04/10/2025: Policy description updated regarding devices. Policy statements unchanged.
Blue Cross Blue Shield Association policy # 7.01.05
This may not be a comprehensive list of procedure codes applicable to this policy.
The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.
Code Number | Description | ||
CPT-4 | |||
69930 | Cochlear device implantation, with or without mastoidectomy | ||
69949 | Unlisted procedure, inner ear | ||
92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual) | ||
92508 | Treatment of speech, language, voice, communication, and/or auditory processing disorder (includes aural rehabilitation); group, two or more individuals | ||
92601 | Diagnostic analysis of cochlear implant, patient under 7 years of age; with programming | ||
92602 | Diagnostic analysis of cochlear implant, patient under 7 years of age; subsequent reprogramming | ||
92603 | Diagnostic analysis of cochlear implant, age 7 years or older; with programming | ||
92604 | Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming | ||
HCPCS | |||
L8614 | Cochlear device, includes all internal and external components | ||
L8615 | Headset/headpiece for use with cochlear implant device, replacement | ||
L8616 | Microphone for use with cochlear implant device, replacement | ||
L8617 | Transmitting coil for use with cochlear implant device | ||
L8618 | Transmitter cable for use with cochlear implant device or auditory osseointegrated device, replacement | ||
L8619 | Cochlear implant external speech processor, replacement | ||
L8623 | Lithium Ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each | ||
L8624 | Lithium Ion battery for use with cochlear implant or auditory osseointegrated device speech processor, ear level, replacement, each | ||
L8625 | External recharging system for battery for use with cochlear implant or auditory osseointegrated device, replacement only, each | ||
L8627 | Cochlear implant, external speech processor, component, replacement | ||
L8628 | Cochlear implant, external controller component, replacement | ||
L8629 | Transmitting coil and cable, integrated, for use with cochlear implant device, replacement | ||
ICD-9 Procedure | ICD-10 Procedure | ||
20.96 | Implantation or replacement of cochlear prosthetic device, not otherwise specified | 09HD0SZ | Insertion of hearing device into right inner ear, open approach |
09HE0SZ | Insertion of hearing device into left inner ear, open approach | ||
20.97 | Implantation or replacement of cochlear prosthetic device, single channel | 09HD05Z | Insertion of single channel cochlear prosthesis into right inner ear, open approach |
09HE05Z | Insertion of single channel cochlear prosthesis into left inner ear, open approach | ||
20.98 | Implantation of replacement of cochlear prosthetic multiple channel device | 09HD06Z | Insertion of multiple channel cochlear prosthesis into right inner ear, open approach |
09HE06Z | Insertion of multiple channel cochlear prosthesis into left inner ear, open approach | ||
20.99 | Other operations on middle and inner ear | 09PD0SZ | Removal of hearing device from right inner ear, open approach |
09PD7SZ | Removal of hearing device from right inner ear, via natural or artificial opening | ||
09PE0SZ | Removal of hearing device from left inner ear, open approach | ||
09PE7SZ | Removal of hearing device from left inner ear, via natural or artificial opening | ||
09WD0SZ | Revision of hearing device in right inner ear, open approach | ||
09WD7SZ | Revision of hearing device in right inner ear, Via natural or artificial opening | ||
09WE0SZ | Revision of hearing device in left inner ear, open approach | ||
09WE7SZ | Revision of hearing device in left inner ear, via natural or artificial opening | ||
95.49 | Other nonoperative procedures related to hearing | F0BZ01Z | Cochlear implant rehabilitation treatment using audiometer |
F0BZ02Z | Cochlear implant rehabilitation treatment using sound field / booth | ||
F0BZ09Z | Cochlear implant rehabilitation treatment using cochlear implant equipment | ||
F0BZ0KZ | Cochlear implant rehabilitation treatment using audiovisual equipment | ||
F0BZ0PZ | Cochlear implant rehabilitation treatment using computer | ||
F0BZ0YZ | Cochlear implant rehabilitation treatment using other equipment | ||
ICD-9 Diagnosis | ICD-10 Diagnosis | ||
389.10 | Sensorineural hearing loss, unspecified | H90.5 | Unspecified sensorineural hearing loss |
389.11 | Sensory hearing loss, bilateral | H90.3 | Sensorineural hearing loss, bilateral |
389.12 | Neural hearing loss, bilateral | ||
389.18 | Sensorineural hearing loss, bilateral | ||
389.14 | Central hearing loss | H90.3 | Sensorineural hearing loss, bilateral |
H90.41 | Sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side | ||
H90.42 | Sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side | ||
H90.5 | Sensorineural hearing loss, bilateral | ||
389.16 | Sensorineural hearing loss, asymmetrical | H90.5 | Sensorineural hearing loss, bilateral |
H90.A21, H90.A22 | Sensorineural hearing loss, unilateral, with restricted hearing on the contralateral side | ||
389.7 | Deaf, nonspeaking, not elsewhere classifiable | H91.3 | Deaf nonspeaking, not elsewhere classified |
CPT copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.